Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Treasury Shares (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Treasury Shares for 11 consecutive years, with $736272.0 as the latest value for Q1 2026.

  • For Q1 2026, Treasury Shares rose 28.58% year-over-year to $736272.0; the TTM value through Mar 2026 reached $736272.0, up 28.58%, while the annual FY2025 figure was $522498.0, 17.62% up from the prior year.
  • Treasury Shares hit $736272.0 in Q1 2026 for Cartesian Therapeutics, up from $522498.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.5 million in Q1 2023 and bottomed at $444238.0 in Q4 2024.
  • Average Treasury Shares over 5 years is $1.1 million, with a median of $654438.5 recorded in 2025.
  • Year-over-year, Treasury Shares soared 332.39% in 2022 and then plummeted 81.16% in 2024.
  • Cartesian Therapeutics' Treasury Shares stood at $1.7 million in 2022, then rose by 20.37% to $2.1 million in 2023, then plummeted by 78.36% to $444238.0 in 2024, then grew by 17.62% to $522498.0 in 2025, then skyrocketed by 40.91% to $736272.0 in 2026.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $736272.0, $522498.0, and $523254.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.